IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma

Core Insights - IN8bio, Inc. reported updated clinical data from its INB-200 Phase 1 and INB-400 Phase 2 trials for newly diagnosed glioblastoma (GBM), showing significant improvements in progression-free survival compared to historical standard-of-care data [1][4] Clinical Trial Results - Patients receiving DeltEx™ Drug-Resistant Immunotherapy γδ T cells (DeltEx DRI) demonstrated a median progression-free survival (mPFS) of 13.0 months, nearly double the 6.6 months observed in the standard-of-care (SOC) control cohort, representing a 97% improvement [4][5] - The median overall survival (mOS) for DeltEx DRI patients is currently at 17.2+ months, compared to 13.2 months for SOC, indicating a 30.3% increase [4][5] - Eight out of fourteen DeltEx DRI patients (57%) remained progression-free longer than their expected overall survival based on age and MGMT status, while only one patient (10%) in the control group achieved this [5] Safety Profile - The DeltEx DRI treatment exhibited a well-tolerated safety profile, with no severe adverse events (SAEs) or dose-limiting toxicities (DLTs) reported [4][6] - No cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity (ICANS) was observed, further supporting the safety of the treatment [6][9] Immune Response Insights - Elevated levels of γδ T cells were observed in treated patients, along with immune cell infiltration within tumors and broader systemic immune activation, suggesting a significant immune impact [7] - The localized intracranial delivery of DeltEx DRI may drive systemic immune responses, which is crucial for combating GBM, a disease characterized by rapid progression and poor outcomes [7] Company Background - IN8bio is a clinical-stage biopharmaceutical company focused on developing γδ T cell therapies for unmet medical needs, including programs targeting acute myeloid leukemia and glioblastoma [8]